Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations
- 19 November 2018
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 174 (1) , 55-63
Abstract
The human epidermal growth factor receptor 2 (ERBB2) may harbour somatic mutations that drive breast tumorigenesis. Here, we study prevalence, tumour characteristics and disease outcome of ERBB2 mutations in a large unselected cohort of metastatic breast cancer (mBC) patients.Keywords
Funding Information
- Puma Biotechnology, Inc.
This publication has 21 references indexed in Scilit:
- The prognostic effects of somatic mutations in ER-positive breast cancerNature Communications, 2018
- HER kinase inhibition in patients with HER2- and HER3-mutant cancersNature, 2018
- Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further ResearchAdvances in Anatomic Pathology, 2017
- Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literatureBreast Cancer Research and Treatment, 2017
- Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer SubtypeJournal of Clinical Oncology, 2017
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831Journal of Clinical Oncology, 2014
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014Annals of Oncology, 2014
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast CancerCancer Discovery, 2013
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trialThe Lancet Oncology, 2011
- Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant ChemotherapyJournal of Clinical Oncology, 2007